Integra LifeSciences (IART) reported Q2 EPS of $0.82, $0.02 better than the analyst estimate of $0.80. Revenue for the quarter came in at $398 million versus the consensus estimate of $395.65 million.
GUIDANCE:
Integra LifeSciences sees FY2022 EPS of $3.21-$3.29, versus the consensus of $3.31. Integra LifeSciences sees FY2022 revenue of $1.56-1.58 billion, versus the consensus of $1.59 billion.